Journal
INTERNATIONAL JOURNAL OF DERMATOLOGY
Volume 47, Issue 10, Pages 1076-1078Publisher
WILEY
DOI: 10.1111/j.1365-4632.2008.03729.x
Keywords
-
Categories
Ask authors/readers for more resources
The role of immune response modifiers is increasing in the treatment of dermatologic diseases. Imiquimod, a toll-like receptor agonist, results in up-regulation of proinflammatory cytokines for improved immune surveillance. Although topical use is generally well-tolerated, imiquimod can potentially result in systemic effects and exacerbate generalized inflammatory papulosquamous diseases of the skin. We report the case of a 67-year-old man who was treated with imiquimod for actinic keratosis and developed fever and a progressive erythematous papulosquamous eruption that was histologically consistent with pityriasis rubra pilaris.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available